 Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI aprepitant injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 COVID-19. The study initiation follows clearance from the U.S. Food and Drug Administration FDA of Herons Investigational New Drug application for CINVANTI for the treatment of COVID-19. 